NCT05428696View on ClinicalTrials.gov

Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 12, 2022

Primary Completion Date

April 24, 2023

Study Completion Date

May 26, 2023

Conditions
Healthy
Interventions
DRUG

ALXN2080

Powder-in-capsule

DRUG

Placebo

Powder-in-capsule

Trial Locations (1)

BT9 6AD

Clinical Trial Site, Belfast

Sponsors

Collaborators (1)

Celerion
All Listed Sponsors
collaborator

Celerion

INDUSTRY

lead

Alexion Pharmaceuticals, Inc.

INDUSTRY